Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Rheumatology and Clinical Immunology, Berlin, Germany.
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Research Group on Geriatrics, Working Group Nutrition and Body Composition, Berlin, Germany.
Nutrition. 2018 Nov;55-56:51-55. doi: 10.1016/j.nut.2018.03.046. Epub 2018 Apr 3.
We analyzed the prevalence of sarcopenia among systemic sclerosis (SSc) patients with respect to quality of life, disability, organ involvement, and muscle function.
A total of 129 patients who met the ACR/EULAR 2013 classification criteria were included. Body composition was measured using bioelectric impedance analysis. Sarcopenia was defined according to the criteria of the European Working Group on Sarcopenia in Older People. Handgrip and knee extension strength and pulmonary peak flow were measured. Physical function was assessed with the Short Form-36 Health Survey and Scleroderma Health Assessment Questionnaire.
Sarcopenia was prevalent in 22.5% of patients. There were significant differences between patients with and without sarcopenia regarding handgrip strength (11.5 [2.0-30.0] versus 18.0 [1.0-41.0] kilogram force [kgf]; P <0.001) and knee extension strength (11.0 [3.5-32.5] versus 17.5 [3.5-88.0] kgf; P = 0.006), physical function (38.8 [9.9-85.0] versus 48.8 [0-88.0]; P = 0.032) and number of immunosuppressants (2 [0-4] versus 1 [0-5]; P = 0.009). There were no differences regarding age (57.0 [32.0-83.0] versus 60.5 [28.0-82.0] years; P = 0.350) and disease duration (8 [1-27] versus 7 [0-34] years; P = 0.350).
Sarcopenia is common in patients with SSc and is associated with physical impairment that affects everyday life and participation in work. Interestingly, although age is the main risk factor for sarcopenia in the general population, it did not differ between sarcopenic and non-sarcopenic SSc patients in our study. Instead, the number of immunosuppressive drugs was significantly higher among sarcopenic patients.
我们分析了伴有生活质量、残疾、器官受累和肌肉功能障碍的系统性硬化症（SSc）患者中肌少症的患病率。
共纳入符合 ACR/EULAR 2013 分类标准的 129 例患者。使用生物电阻抗分析测量身体成分。根据欧洲老年人肌少症工作组的标准定义肌少症。测量握力和膝关节伸展力量以及肺峰流速。使用 36 项简短健康调查问卷和硬皮病健康评估问卷评估身体功能。
22.5%的患者存在肌少症。有肌少症和无肌少症的患者在握力（11.5[2.0-30.0]与 18.0[1.0-41.0]千克力[kgf]；P<0.001）和膝关节伸展力量（11.0[3.5-32.5]与 17.5[3.5-88.0]kgf；P=0.006）、身体功能（38.8[9.9-85.0]与 48.8[0-88.0]；P=0.032）和免疫抑制剂数量（2[0-4]与 1[0-5]；P=0.009）方面存在显著差异。两组间在年龄（57.0[32.0-83.0]与 60.5[28.0-82.0]岁；P=0.350）和疾病持续时间（8[1-27]与 7[0-34]年；P=0.350）方面无差异。
肌少症在 SSc 患者中很常见，与影响日常生活和工作参与的身体功能障碍有关。有趣的是，尽管年龄是一般人群中肌少症的主要危险因素，但在我们的研究中，肌少症和非肌少症 SSc 患者之间并无差异。相反，肌少症患者使用的免疫抑制剂数量明显更高。
